Associated Papers
Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.
Henderson GJ et al.
Antimicrobial Agents and Chemotherapy, 2012
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Weinheimer S et al.
Antimicrobial Agents and Chemotherapy, 2005
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
Svicher V et al.
Antimicrobial Agents and Chemotherapy, 2005
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D et al.
Antiviral Therapy, 2004
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
Sugiura W et al.
Antimicrobial Agents and Chemotherapy, 2002
Select a paper to view details